03 jan: Investeringsforeningen Formuepleje – Forventede udbytter for 2018
03 jan: FN 1/2019 FastPassCorp A/S skifter certified advisor
03-01-2019 09:48:11

Genmab to Present at the 37th Annual J.P. Morgan Healthcare Conference

Media Release

Copenhagen, Denmark, January 3, 2019

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at 3:30 PM PST on January 9, 2019 (12:30 AM CET, January 10).  A webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events.cfm.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; E: rcg@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 01

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jun - 
Genmab: Blackrock er tilbage i storaktionærklubben
12 jun - 
Genmab/Jyske: Forsinket godkendelse har øget risiko for..
11 jun - 
Tirsdagens aktier: Ambu og Novo toppede marked klædt i ..
Relateret debat
20 jun - 
De gør som de plejer, tager en slapper fra morgenen af ..
19 jun - 
God signalværdi
19 jun - 
Interessant 👍
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jun
GEN
Black Rock ligger lige nu med Ca 5% af alle Genmab aktier, de ligger og svinger på lige over og unde..
3
19 jun
GEN
God signalværdi
2
19 jun
GEN
Interessant 👍
1
19 jun
GEN
Nu over igen... Lad os håbe de har appetit på mange flere... Og at nogle shorts snart skal indløses...
1

Euroinvestor spørger: Tryg-aktien stormer frem, kan den blive ved?

23-06-2019 20:35:00
Hos Euroinvestor mener vi, at den bedste kilde til viden om markedet er aktørerne i markedet.Derfor spørger vi hver måned i vores Privatinvestorundersøgelse (PIU) vores brugere om deres forventninger til markeder og økonomi.Du inviteres hermed til at deltage i undersøgelsen. Alle besvarelser er anonyme, og der er ingen krav om login, kontaktoplysninger eller lignende.Vi håber du vil deltage og ser..

Danske Bank: Bestyrelsen fyrer bankdirektør Jesper Nielsen

24-06-2019 08:35:10
Danske Banks bestyrelse har mandag opsagt bankdirektør Jesper Nielsen, der har ansvar for de danske bankaktiviteter.Det fremgår af en meddelelse til fondsbørsen.Opsigelsen sker i forbindelse med sagen om Flexinvest Fri, lyder det.- Jesper Nielsen har gjort en betydelig indsats i banken gennem mange år, senest som midlertidig administrerende direktør, hvilket vi takker ham for.- Men i den konkrete ..

Aktier/tendens: Ørsted står til stigning efter stor sejr i USA

24-06-2019 08:09:35
Efter at have trukket sig sejrrigt ud af en budrunde i USA står Ørsted over for en positiv mandag, mens det generelle danske aktiemarked ligger til en mere moderat udvikling.Godt en time før børsåbning herhjemme peger de amerikanske indeksfutures mod mindre stigninger, og det samme gør den britiske FTSE 100-future. Omvendt indikerer den tyske DAX-future et lille fald.Udsigten til en mandag morgen ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank: Bestyrelsen fyrer bankdirektør Jesper Nielsen
2
Dybvad: Så alvorlig en sag at vi måtte skride til fyring
3
Danske Bank: Finanstilsynet kalder sag for "meget alvorlig"
4
Aktier/middag: Danske Bank bankes ned efter farvel til CEO-vikar
5
Aktier/tendens: Ørsted står til stigning efter stor sejr i USA

Relaterede aktiekurser

Genmab A/S 1.201,00 0,0% Aktiekurs uændret

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. juni 2019 18:05:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-24 18:05:49 - 2019-06-24 18:05:49 - 1 - Website: OKAY